The start of a new year is a great time to review what happened over the last 12 months and take some lessons from it. So, as ...

1421 ET – Biotech’s year ahead looks uncertain, but it could still be a safer option in a market downturn, Baird analysts say. The unknowns of a Trump administration, including possible ...

This is why Roundup by the end of 2003 was now the choice for 1 in 4 gardeners versus 1 in 10 prior to the campaign 36. And why more and more people were saying that it was the most effective ...

The free agency period opens in one day, but the lack of all-star talent available has teams turning to the trade market to improve ... deal for a scoring forward. Still, there should be enough ...

we are doing things differently for the last roundup of the year, reviewing all of 2024 and the trends, themes, and stories that defined it. It was tough going in the art market, where slumped ...

The company still designs the best AI chips ... After all, Stock Advisor’s total average return is 891% — a market-crushing outperformance compared to 173% for the S&P 500.* ...

CagriSema could still become the drug with the best weight-loss efficacy to date and its performance on that front doesn’t look as disappointing as the market reaction suggests, according to ...

The company still designs the best AI chips ... John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a ...